home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2893.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
33 lines
Document 2893
DOCN M94A2893
TI Treatment with intravenous immunoglobulin in severe Guillain-Barre
syndrome and HIV infection.
DT 9412
AU Rodriguez Arrondo F; Huarte I; Von Wichmann MA; Iribarren JA;
Arrizabalaga J; Urtasun M; Infectious Diseases Unit, Hospital Ntra Sra
Aranzazu, San; Sebastian, Spain.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):200 (abstract no. PB0228). Unique
Identifier : AIDSLINE ICA10/94369682
AB OBJECTIVE: To determine the Efficacy and safety of High-dose intravenous
immunoglobulin in the treatment of severe Guillain-Barre syndrome (GBS)
in patients with HIV infection. METHODS: Two severely affected patients
were treated with five doses of a preparation of immunoglobulin (0.4 g
per kilogram daily). Treatment was started within 2 weeks after onset.
Clinical improvement and drug toxicity were evaluated by recovery time,
neurological scores and vital capacity and drug toxicity. RESULTS:
Clinical response was excellent in both patients receiving intravenous
immunoglobulin; their neurologic disability score and vital capacity
improved within a few days. There was no recurrence during follow up
periods of 12 months. No side-effects were noted. CONCLUSION:
Immunoglobulin is a practical, safe and effective treatment for GBS and
HIV infection. We believe that High-dose intravenous immunoglobulin
should be the first choice of therapy in severe illness. Further
experience in larger number of patients is necessary.
DE Drug Evaluation Human HIV Infections/*COMPLICATIONS Immunoglobulins,
Intravenous/*THERAPEUTIC USE
Polyradiculoneuritis/COMPLICATIONS/*THERAPY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).